Tyrosine kinase inhibitorPhase 3 trialInvestigational
Midostaurin
How it works
Blocks the FLT3 tyrosine kinase enzyme, which is overactive in AML cells, and also inhibits other tyrosine kinases involved in cancer growth.
Cancer types
Leukemia— FLT3-mutated
Efficacy
In clinical trials, around 50% of FLT3-mutated patients achieved a complete remission, with a median overall survival of approximately 10 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Midostaurin in Combination with Chemotherapy for Pediatric AML | Leukemia | phase-2 | — | Source → |
| Combining Midostaurin with CLAG-M Chemotherapy for AML | Leukemia | observational | The rate of complete remission (CR) plus CR with incomplete blood count recovery did not significantly differ between the 2 cohorts: CLAG-M, 86% versus 7+3, 70%. | Source → |
| New Study Examines Prognostic Scores for Advanced Mastocytosis Patients | Leukemia | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.